ada.enesco, Author at European Medical Journal - Page 28 of 65

Advancements in Laparoscopic Surgery for Early Prostate Cancer

Recent research comparing laparoscopic and open radical prostatectomy outcomes shows that radical prostatectomy leads to shorter hospital stays.

Researchers Reveal the Alarming Long-Term Risks of Steroid Use

Long-term study reveals alarming cardiovascular risks in steroid users, with some heart conditions up to nine times more likely.

Researchers Discover Drivers of Prostate Cancer Evolution

A study of 666 localised prostate tumours identified 223 driver regions, many influenced by structural variations undetectable via targeted sequencing.

Sotatercept Shows Long-Term Benefit in Pulmonary Arterial Hypertension Treatment

Interim findings from the ongoing SOTERIA study suggest that sotatercept provides a favourable long-term safety and efficacy profile for adults with pulmonary arterial hypertension.

A Promising Biomarker for Predicting Acute-on-Chronic Liver Failure: ECR 2025

A recent study presented at ECR 2025 has identified the Functional Liver Imaging Score as a valuable prognostic biomarker for predicting acute-on-chronic liver failure.

Nasal Spray Immunomodulation: A Novel Approach to Treating TBI

Nasal spray shows promise in treating traumatic brain injury by reducing inflammation and enhancing immune cell function in mouse models.

New Study Reveals Link Between Insulin and Obesity Development

New findings shed light on the brain’s role as a critical control centre in the development of obesity and Type 2 diabetes.

How the Mediterranean Diet Lowers Obesity-Related Cancer Risk

The EPIC study found that higher Mediterranean diet adherence correlated with a 4% reduction in overall cancer risk.

Managing Factor Xa Inhibitors Perioperatively: PERIXa Shows Promise

New study finds the PERIXa protocol for perioperative anticoagulation in AF patients undergoing low-risk procedures is safe.

Exploring Bladder Preservation in Muscle-Invasive Bladder Cancer Treatment

The combination of durvalumab and tremelimumab with concurrent radiotherapy is a feasible and safe treatment strategy.